PERFORMANCE PROGRESS and MONITORING REPORT
Turnaround Time (TAT) Performance

Form Approved
OMB No: 0920-1132
Exp. Date: 3/31/2026

1. Submitting Laboratory			2. Laboratory Contact				3. Reporting Period
(1) TAT Performance Indicator	**(2) Recommendation**	**(3) Benchmark**	**(4) National Target**	**(5) Testing Method**	**(6) PHL TAT: CY2023**	**(7) PHL Goal**	**(8) Comments/Obstacles to Meeting National Target**
1	Promote rapid delivery of specimens to the laboratory.	Percentage of specimens received within one day of specimen collection.	≥67%	NA			
1a		Percentage of specimens received within two days of specimen collection.		NA		NA	
1b		Percentage of specimens received within three days of specimen collection.		NA		NA	
2	Use fluorescent acid-fast staining and promptly transmit results.	Percentage of smear results reported within one day of receipt of specimen.	≥92%				
2a		Percentage of smear results reported within two days of receipt of specimen.		NA		NA	
2b		Percentage of smear results reported within three days of receipt of specimen.		NA		NA	
3	Promote use of NAAT.	Report percent of patients tested by NAAT that had a positive result reported within 48 hours of specimen receipt.	≥77%				
4	Use rapid methods to identify and report isolates as MTBC as soon as possible.	Report percent of MTBC isolates identified from initial diagnostic specimens within 21 calendar days of receipt.	≥74%				

5	Determine susceptibilities of initial MTBC isolates to first-line drugs in a rapid culture system and report results promptly.	Report percent of rifampin results reported for initial diagnostic specimens within 17 days of ID of MTBC from culture. *Note: Do not include molecular sequencing DST data; this data is collected in 6-6a.* *Note: Isolates sent out for referral testing should be included.*	≥69%				
6	For laboratories that perform in-house molecular sequencing DST methods, report specimen and/or MTBC isolate results. *Note: Not every public health laboratory will have sufficient volume or capacity to perform this testing.* *Note: Probe-based methods such as Xpert® MTB/RIF and line probe assays should <u>not</u> be included.*	For laboratories that perform **in-house** molecular sequencing DST methods on <u>specimens</u>*, report percent of results reported within 11 days. Also, report the mean and range TAT in days. *Measure from date of receipt to result report.	≥75%	*Method 1*	Percent meeting benchmark Mean TAT Range TAT		
				Method 2	Percent meeting benchmark Mean TAT Range TAT		
6a		For laboratories that perform **in-house** molecular sequencing DST methods on <u>isolates</u>**, report percent of results reported within 11 days. Also, report the mean and range TAT in days. **Measure from date of receipt (if a referred isolate) or date of ID (if ID is performed in-house) to result report.	≥75%	*Method 1*	Percent meeting benchmark Mean TAT Range TAT		
				Method 2	Percent meeting benchmark Mean TAT Range TAT		

7	For laboratories that perform in-house IGRA testing methods, report results promptly.	For laboratories that perform in-house IGRA testing, report percent of results reported within 4 days. Also, report the mean TAT in days between specimen collection and reporting of IGRA test result.	≥75%		Percent meeting benchmark Mean TAT		

Line-Item Instructions

Item	Data Elements	Instructions
1	Submitting Laboratory	Enter the name of the awarding laboratory that the data is from.
2	Laboratory Contact	Enter the name of the laboratory contact submitting this data.
3	Reporting Period	Enter the reporting period state and end date.
TAT Performance		
(1)	TAT Performance Indicator	Indicator number of TAT performance activity.
(2)	Recommendation	Corresponding recommendation associated with the particular performance measure.
(3)	Benchmark	Description of requested performance measure data.
(4)	National Target	National target percentage related to each measure.
(5)	Testing Method	Enter testing methods used to accomplish the recommendations.
(6)	Public Health Laboratory (PHL) TAT for CY 2023	Enter cumulative measure TAT percentage achieved as of the end of 2023.
(7)	PHL Goal	Enter current PHL internal goals as a percentage for the performance measures.
(8)	Comments/Obstacles to Meeting Target/Goal	List specific comments or obstacles to meeting the national targets.